Overview

Alan Menter, MD, discusses best practices in establishing disease severity in patients with plaque psoriasis, the efficacy and safety of established and newly approved systemic therapies for treating patients with moderate-to-severe disease, and how to optimize treatment for patients with chronic plaque psoriasis.

Discover the foremost questions dermatologists have about moderate-to-severe plaque psoriasis.

Probe details of a related patient case.

Content Areas

  • Assessing psoriasis severity
  • Comorbidity evaluation
  • Tumor necrosis factor-alpha antagonists
  • Newly approved IL-17/IL-23 agents
  • Emerging oral therapies

Target Audience

This activity was developed for dermatologists, dermatology fellows, advanced nurse practitioners, physician assistants and other health care professionals who have an interest in moderate-to-severe plaque psoriasis.


This activity is supported by an independent educational grant from Novartis Pharmaceuticals Corporation.

Faculty

Alan Menter, MD
Alan Menter, MD
Chair, Division of Dermatology
Baylor University Medical Center
Clinical Professor of Dermatology
University of Texas Southwestern Medical Center
Dallas, Texas
Enter your information to begin.
CME Credit
Available Credit: 1.00 AMA PRA Category 1 Credit™.
1.00 AANP Contact Hour
1.00 ANCC Contact Hour
Opens: September 29, 2017
Expires: September 28, 2018
Target Audience: Dermatologists
Fellows
Nurse Practitioners
Physician Assistants
Other Health Care Providers